U.S. Markets closed

TransCode Therapeutics Announces Participation in the Q4 Virtual Investor Summit

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • RNAZ

Boston, Massachusetts--(Newsfile Corp. - November 9, 2021) - TransCode Therapeutics, Inc. (NASDAQ: RNAZ) today announced that it will be attending and presenting at the Q4 Virtual Investor Summit. TransCode's Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based scientific discoveries that it believes will significantly advance the treatment of cancer, including the company's lead therapeutic candidate treating metastatic disease which it is advancing into the clinic with its First in Human clinical trial planned for mid-next year. The presentation will be webcast and an archived recording will be made available in Investors' section of the TransCode Therapeutics website.

Event:

Q4 Investor Summit

Date:

November 16-17th, 2021

Presentation:

November 17th at 10:15AM ET

Location:

https://us06web.zoom.us/webinar/register/WN_P1C4IlpCSEi4d5wjRmsVqA

  • 1x1s will be available for qualified investors

  • The conference is completely complimentary to qualified investors. Please register at Complimentary Investor Registration

  • An archived replay of TransCode Therapeutics presentation will be available immediately after the presentation via the Webcast link. The presentation will also live on the Investor Summit website for 90 days after the event.

About TransCode Therapeutics

TransCode's Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based scientific discoveries that it believes will significantly advance the treatment of cancer, including the company's lead therapeutic candidate treating metastatic disease which it is advancing into the clinic with its First in Human clinical trial planned for mid-next year. The presentation will be webcast and an archived recording will be made available in Investors' section of the TransCode Therapeutics website.

For further information:

TransCode Therapeutics, Inc.
Tom Fitzgerald, CFO
tom.fitzgerald@transcodetherapeutics.com

About the Investor Summit

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q4 Investor Summit will take place virtually, featuring 90+ companies and over 500 investors comprising of institutional investors, family offices, and high net worth investors. Sectors Participating: Biotech, Communication Services, Consumer, Energy, Energy/Tech, Financial, Healthcare, Industrials, Materials, Real Estate, Technology, and Tech/Crypt. Contact: info@investorsummitgroup.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/102515